

# MAPS in the Media

## The New York Times

### A Psychedelic Drug Passes a Big Test for PTSD Treatment

Rachel Nuwer • May 3, 2021

“In an important step toward medical approval, MDMA . . . was shown to bring relief to those suffering from severe post-traumatic stress disorder when paired with talk therapy,” says The New York Times in exclusive coverage. “Two months after treatment, 67 percent of participants in the MDMA group no longer qualified for a diagnosis of PTSD, compared with 32 percent in the placebo group.” The first completed MAPS-sponsored Phase 3 clinical trial of MDMA-assisted therapy for PTSD shows positive peer-reviewed results, marking a historic point in the field of psychedelic science.

## RollingStone

### Phase 3 Trial Shows Promising Results for MDMA-Assisted PTSD Therapy

Jon Blistein • May 4, 2021

“As is widely known, MDMA boosts serotonin, oxytocin, and dopamine to create feelings of euphoria, empathy, trust, and compassion; in a therapeutic context, it also seems capable of re-opening what neuroscientists call the “critical period” — a moment in childhood where the brain is capable of making and storing new memories.”

## The New York Times

### The Psychedelic Revolution Is Coming. Psychiatry May Never Be the Same.

Andrew Jacobs • May 9, 2021

MAPS is featured in an article on the front page of May 9 edition of The New York Times! Reporter Andrew Jacobs profiles MAPS Founder and Executive Director Rick Doblin, Ph.D., and highlights the success of MAPS' first Phase 3 study of MDMA-assisted therapy for PTSD, the results of which were published in Nature Medicine earlier today. “After decades of demonization and criminalization,” explains Jacobs, “psychedelic drugs are on the cusp of entering mainstream psychiatry, with profound implications for a field that in recent decades has seen few pharmacological advancements for the treatment of mental disorders and addiction.”

## RollingStone

### How a Psychedelics Call-In Line is Helping People Trip Better

Delilah Friedler • July 7, 2021

Rolling Stone profiles Fireside Project's Psychedelic Peer Support Line, highlighting the experience of a caller who recently utilized the free harm reduction service.



### How MDMA-Assisted Therapy Could Treat PTSD in Ways Current Therapy Can't

Nicholas Nissen • May 13, 2021

In an article featuring the perspective of MAPS Founder and Executive Director Rick Doblin, Ph.D., ABC News covers MAPS' efforts to make MDMA-assisted therapy for PTSD a legal prescription medicine, focusing primarily on the successful results of the Phase 3 clinical trial of MDMA-assisted therapy for PTSD, which was sponsored by MAPS and published last week in Nature Medicine. Doblin cautions, however, that although the historic study is now published, “the hardest parts are still ahead.”



### The Case for Using MDMA to Help Heal Victims of Trauma

Scott Shannon • May 18, 2021

“In the 30 years since the pharmaceutical revolution began, psychiatry may be the only medical field to lose ground to its diseases,” says Scott Shannon, M.D. “Until MDMA, perhaps.”



## A New Study Points to MDMA as a Powerful Treatment for PTSD

Jeffrey Kluger • May 11, 2021

TIME contextualizes the findings of the first Phase 3 clinical trial of MDMA-assisted therapy for PTSD, providing a brief overview of the challenges that face people who experience PTSD, as well as the MAPS-sponsored study's statistically significant results. "I speculate that the demand will be unprecedented," says Jennifer Mitchell, Ph.D., lead author of the study. "There are so many people suffering from PTSD and the current treatment options leave much to be desired."



## Psychedelics in Psychiatry: New Data Supporting an Old Idea

Joe Pierre, M.D. • May 3, 2021

"This is an important study because it's the largest study done to date, with results that—similar to previous smaller studies—are encouraging."



## MDMA Could Help Trauma Survivors Face Painful Memories

Rachel Schraer • May 13, 2021

BBC News provides their international audience with an in-depth overview of Nature Medicine's publication of peer-reviewed results from the MAPS-sponsored Phase 3 clinical trial of MDMA-assisted therapy for posttraumatic stress disorder (PTSD), including expert perspectives on the data, scientific education about trauma, and details about the pathway toward making MDMA-assisted therapy a legal prescription treatment option for PTSD.

"This trial, run by US charity the Multidisciplinary Association for Psychedelic Studies [MAPS], found 88% of people had a 'meaningful reduction in symptoms' and 67% no longer qualified for a PTSD diagnosis at all after 18 weeks and three sessions of MDMA-assisted therapy," reports Rachel Schraer of BBC News. "[MAPS'] chief scientific officer Dr. Berra Yazar-Klosinski said MDMA could be legalised and available for prescription by 2023 in the US, and this summer she plans to travel to Europe to begin the process of seeking regulatory approval from the EU and the UK."



## A Psychedelic Drug Boom in Mental Health Treatment Comes Closer to Reality

Eric Rosenbaum • May 10, 2021

In a new article from CNBC, journalist Eric Rosenbaum explores how the first completed Phase 3 clinical trial investigating the treatment of posttraumatic stress disorder (PTSD) with MDMA-assisted therapy is leading to a "psychedelic drug boom in mental health treatment," referencing the recent peer-reviewed publication of results from the MAPS-sponsored research in Nature Medicine. CNBC highlights how the promising results are supporting potential prescription use of MDMA-assisted therapy becoming approved by the FDA by 2023, noting that future access to psychedelic therapy may help mitigate the increasing prevalence of mental health conditions impacting large portions of the world.

# MAPS in the Media, continued

## SCIENTIFIC AMERICAN

### MDMA Shows New Promise for Trauma, but the Drug Alone Is Not a Cure

Zoe Cormier • May 12, 2021

Scientific American explores how the future of mental healthcare may be impacted by MAPS' first Phase 3 trial of MDMA-assisted therapy for PTSD, the results of which were published one week ago in Nature Medicine. In the article, MAPS Founder and Executive Director Rick Doblin, Ph.D., reflects on the success of the study, stating, "I expected this to work, but the big surprise was how statistically significant it was."

## Newsweek

### Psychedelic Drug Shows Great Promise As Mental Health Treatment, New Study Finds

Adam Piore • May 10, 2021

"What the MDMA clearly did, is it allowed people to go into dark places where ordinarily they did not want to go," says Bessel van der Kolk, M.D., a Principal Investigator of MAPS' Phase 3 trial of MDMA-assisted therapy for PTSD, in Newsweek. "Sometimes they were quite upset during the sessions. But they always came up with unexpected attitude changes, insights, insights that were more than just intellectual, that often gave them an entirely different orientation towards themselves. Self-forgiveness became a very important part of it also, replacing self-blame for what happened."

## BARRON'S

### The First Phase 3 Success for Psychedelics Will Pave the Way for an Industry

Bill Alpert • May 11, 2021

Author Bill Alpert of Barron's contrasts MAPS' leading non-profit and public benefit models with the profit-oriented approach of new psychedelic companies. "None of the for-profits are talking about drug policy reform," highlights MAPS Founder and Executive Director Rick Doblin, Ph.D.

## GOOD HOUSEKEEPING

### Are Psychedelics the Next Big Cure?

Meryl Davids Landau • June 10, 2021

Psychedelic research "studies that have been completed, while preliminary, have been nothing short of amazing," declares Good Housekeeping, as advancements in psychedelic science continue to reach new audiences.



**The Joe Rogan Experience: #1661 – Rick Doblin, Ph.D.**

Joe Rogan • June 4, 2021

Joe Rogan hosts MAPS Founder and Executive Director Rick Doblin, Ph.D., for his third appearance on the Joe Rogan Experience, one of the top podcasts in the world! Listen to the brand new, long-form podcast episode for a dynamic overview of MAPS' recent accomplishments in the field of psychedelic science and how you can sustain MAPS' mission moving forward.

# healthline

**Psychedelic Therapy Is Having a Moment – Here's What You Need to Know**

Kate Robertson • May 25, 2021

Healthline provides a well-rounded overview about the basics of psychedelic-assisted therapy, including the current research applications and statuses of various psychedelics, stages of the therapeutic process, and potential risks associated with psychedelic use.

# The Guardian

**The Psychologists Signing Up for Psychedelic Therapy Training: 'Amazing Things Can Happen'**

Jenny Valentish • May 29, 2021

The Guardian reports on the psychedelic renaissance in Australia, profiling the experiences of several mental health professionals who are undergoing training in psychedelic-assisted therapy and highlighting the decision of Australia's federal government "to back psychedelic clinical trials with \$15m."



**How MDMA Can be Used to Treat Severe Post-Traumatic Stress Disorder**

May 18, 2021

"MDMA was a therapy drug before it became a party drug," says MAPS Founder and Executive Director Rick Doblin, Ph.D., in an interview with NBC News Now, "and we're trying to bring it back to being a therapy drug."



**Brookline Therapists See PTSD Patients Improve Significantly With Experimental Ecstasy Therapy**

Liam Martin • June 29, 2021

MAPS-sponsored therapists join CBS Boston to discuss MAPS' first Phase 3 trial of MDMA-assisted therapy for PTSD, including details about the therapeutic process and study results. Boston-based therapist Jim Hopper, Ph.D., points out the importance of a study participant's "inner healing intelligence" throughout the MDMA-assisted therapy sessions.

# BUSINESS INSIDER

**Experts Share How a Brewing Fight Could Shape the Future of the \$100 Billion Psychedelics Industry**

Yeji Jesse Lee • June 2, 2021

"Rick Doblin, the organization's founder and executive director, said he isn't interested in filing patents related to its work with MDMA. Instead, MAPS is focused on data exclusivity, a protected period of time granted to FDA-approved treatments before rivals can sell similar versions."